Focus: Bicycle Therapeutics is a Cambridge-based biotech company specializing in peptide-based therapeutics for oncology, leveraging its proprietary bicyclic peptide platform technology.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
3 added, 5 removed. Backfill posture.
Best suited for scientists and development professionals seeking deep involvement in novel modality research at a focused, pre-scale biotech; career growth limited by company size and early pipeline maturity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bicycle Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bicycle Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - BioSpace
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results BioSpace
BCYC|Bicycle Therapeutics PLC|Price:3.870|Chg%:-0.070 - TradingKey
BCYC|Bicycle Therapeutics PLC|Price:3.870|Chg%:-0.070 TradingKey
Bicycle Therapeutics sharpens new weaponry to fight bladder cancer - Business Weekly
Bicycle Therapeutics sharpens new weaponry to fight bladder cancer Business Weekly
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting - Yahoo Finance
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting Yahoo Finance
Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC) - Stock Titan
Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC) Stock Titan
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo